Bank of New York Mellon’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-417,942
| Closed | -$3.75M | – | 4412 |
|
|
2016
Q3 | $3.75M | Sell |
417,942
-37,449
| -8% | -$266K | ﹤0.01% | 2387 |
|
|
2016
Q2 | $2.45M | Buy |
455,391
+11,837
| +3% | +$60.7K | ﹤0.01% | 2591 |
|
|
2016
Q1 | $2.04M | Buy |
443,554
+26,256
| +6% | +$106K | ﹤0.01% | 2648 |
|
|
2015
Q4 | $2.17M | Buy |
417,298
+15,255
| +4% | +$88.5K | ﹤0.01% | 2667 |
|
|
2015
Q3 | $2.43M | Sell |
402,043
-59,707
| -13% | -$732K | ﹤0.01% | 2610 |
|
|
2015
Q2 | $7.29M | Buy |
461,750
+82,074
| +22% | +$997K | ﹤0.01% | 2122 |
|
|
2015
Q1 | $4.13M | Buy |
379,676
+12,376
| +3% | +$126K | ﹤0.01% | 2419 |
|
|
2014
Q4 | $3.86M | Buy |
367,300
+2,781
| +0.8% | +$27.2K | ﹤0.01% | 2446 |
|
|
2014
Q3 | $3.5M | Buy |
364,519
+32,246
| +10% | +$329K | ﹤0.01% | 2522 |
|
|
2014
Q2 | $3.84M | Buy |
332,273
+4,650
| +1% | +$42.3K | ﹤0.01% | 2479 |
|
|
2014
Q1 | $3.28M | Sell |
327,623
-1,355
| -0.4% | -$19.6K | ﹤0.01% | 2563 |
|
|
2013
Q4 | $4.28M | Sell |
328,978
-37,066
| -10% | -$510K | ﹤0.01% | 2394 |
|
|
2013
Q3 | $5.46M | Buy |
366,044
+33,590
| +10% | +$402K | ﹤0.01% | 2190 |
|
|
2013
Q2 | $3.11M | Buy |
+332,454
| New | +$2.25M | ﹤0.01% | 2496 |
|
Bank of New York Mellon's RPTP Position: Q4 2016 in Review
Bank of New York Mellon sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q4 2016, closing a stake of 417,942 shares — an estimated $3.75M sold.
Bank of New York Mellon first reported a position in RPTP in Q2 2013 and held it in 14 quarters. The position peaked at $7.29M in Q2 2015. 0 funds tracked by Wall St. Rank hold RPTP as of Q4 2016.
- Bank of New York Mellon reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q4 2016 after selling out during the quarter.
- Bank of New York Mellon sold 417,942 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q4 2016, an estimated $3.75M.
- Bank of New York Mellon first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q2 2013 and held it in 14 quarters.
- Bank of New York Mellon's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $7.29M in Q2 2015.
- 0 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q4 2016.
Based on Bank of New York Mellon's 13F filing for Q4 2016, filed 13 Feb 2017.